Since the feasibility of sequencing cfDNA fragments to detect tumour-associated TP53 mutation was first reported more than 15 years ago, studies have demonstrated that TP53 mutation detection can evaluate tumour burden, predict time to progression (TTP) and detect tumour recurrence [58, 91, 162–165, 189, 229, 230]. The gene discussed is TP53; the disease is neoplasm.